HFREF Pharmacological Treatment Sequencing: The Traditional Approach

João Manoel Rossi Neto, Raphael Machado Rossi, Marco Aurelio Finger, Carolina Casadei dos Santos
Instituto Dante Pazzanese de Cardiologia, São Paulo, SP – Brazil

The traditional approach to sequencing

This approach respects the historical introduction of drugs studied and proven by randomized clinical trials (RCTs) and has its use approved by all guidelines. It is important to note that all RCTs on heart failure with reduced ejection fraction (HFrEF) have used this sequencing approach, and when a new drug is tested, it is added to optimized standard therapy. This reinforces the need to maintain triple therapy with a beta-blocker (BB), an angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), and a mineralocorticoid receptor antagonist (MRA). Therefore, this triad is recommended as a key therapy for HFrEF unless drugs are contraindicated or not tolerated.

Angiotensin receptor-neprilysin inhibitors (ARNis; sacubitril/valsartan) should replace ACEis in patients who remain symptomatic despite the triad and may also be considered first-line therapy instead of ACEis (Figure 1). The maximum recommended doses (MRDs) of these drugs are described in the Brazilian Society of Cardiology guidelines.

The sodium-glucose cotransporter 2 inhibitors (SGLT2i) dapagliflozin and empagliflozin (both at starting and target doses of 10 mg once daily), when added to the described therapy (Figure 1), reduced the risk of cardiovascular death and worsening heart failure (HF) in HFrEF, regardless of whether the patient had diabetes.

Therefore, these four drugs, ARNi or ACEi/ARB + BB + spironolactone + SGLT2i, are recommended in all guidelines following the steps described above. Combination of medications that have had an impact on morbidity is also possible, and the choice of these additional therapies should consider the profile of each patient (Figure 1).

A period (3-6 months) for clinical and functional reassessment aims to optimize therapy in an environment favorable to a progressive increase in MRD/tolerated dose.

The nontraditional approach to sequencing

Recently, nontraditional sequencing approaches (NTSAs) have been proposed. Quadruple therapy should be started as soon as possible, simultaneously, at low doses, using late titration over a short-term period of 4 weeks to 43 days. Despite the strategy having a strong theoretical and logical foundation, targeting several different pathophysiological steps in a quick sequence, and seeking to break clinical inertia/treat HFrEF with the utmost urgency, the NTSA has never been actually tested. There is no RCT to support this proposal, nor is there full agreement on how quickly and in what order this sequencing should be done or whether this strategy will increase patient compliance. There are only the opinions of renowned investigators, retrospective analyses, and statistical models.

The NTSA can make clinical evaluation difficult, cause side effects (despite the claim to reduce these effects), favor the inertia of therapeutic optimization (“My patient is stable with underdosage”), and cause the continuous risks of sudden death and disease progression to be “forgotten”. Some investigators may have more laboratory experience and do not deal with treatment barriers on a day-to-day basis; there is a large difference between the “theoretical” patient and the “real” patient.

For these reasons, the NTSA has not yet been explicitly incorporated into current HFrEF guidelines, and RCTs are expected to verify its effectiveness and safety.

Keywords
Medication Therapy Management, Heart Failure, Ventricular Ejection Fraction

Mailing Address: João Manoel Rossi Neto •
Ambulatório de Disfunção Ventricular e Transplante de Coração – Av. Dante Pazzanese, 500. Postal Code 04012-909, Ibirapuera, São Paulo, SP – Brazil
E-mail: jmrossi@sti.com.br

Manuscript received January 13, 2022, revised manuscript February 01, 2022, accepted February 14, 2022

DOI: https://doi.org/10.36660/abchf.20220004
Conclusion

The treatment of HFrEF can be laborious and require dedication of a multidisciplinary team to achieve the therapeutic goals of the guidelines, not always available to clinicians working alone in their offices. In this case, the introduction of multiple drugs at the same time may not be the ideal strategy.

Worryingly, there is still inertia in the adoption of recommended treatments, whether because of cost, fear of possible side effects, or ignorance regarding the benefit of therapeutic optimization.

Changing the HFrEF treatment sequence is nothing new and has been discussed in the past,20 with a warning that there is no winner or loser in this fight against HFrEF.

Drugs that reduce morbidity and mortality in HFrEF should be prescribed using published guidelines as a source of knowledge dissemination and standardized continuing medical education. This will avoid confusion for physicians, risk of increased side effects, or use of doses lower than those indicated in guidelines.

In short, the most important task is to ensure access to all evidence-based therapies for all patients with HFrEF.

Author Contributions

Analysis and interpretation of the data and Writing of the manuscript: Rossi Neto JM; Critical revision of the manuscript for intellectual content: Rossi RM, Finger MA, Santos CC.
Potential Conflict of Interest

Dr. João Manoel Rossi Neto presented lectures for Novartis and Astra Zeneca. Dra. Carolina Casadei dos Santos presented lectures for Servier, Novartis, and Boehringer.

Sources of Funding

There were no external funding sources for this study.

References


12. McMurray J, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2021;143(9):875-7. doi: 10.1161/CIRCULATIONAHA.120.052926.


